[1]刘月芬,刘小红,于明军,等.清金化痰汤治疗非小细胞肺癌临床研究[J].陕西中医杂志,2019,(2):229-232.
 LIU Yuefen,LIU Xiaohong,YU Mingjun,et al.Clinical observation of nonsmall cell lung cancer patients treated with Qingjin Huatan decoction[J].,2019,(2):229-232.
点击复制

清金化痰汤治疗非小细胞肺癌临床研究
分享到:

《陕西中医》杂志[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年2期
页码:
229-232
栏目:
临床研究
出版日期:
2019-02-05

文章信息/Info

Title:
Clinical observation of nonsmall cell lung cancer patients treated with Qingjin Huatan decoction
文章编号:
DOI: 10.3969/j.issn.10007369.2019.02.027
作者:
刘月芬1刘小红2于明军1姜祖光1朱明艳1
1.河南省濮阳市油田总医院肿瘤一科(濮阳 457001);2.新乡医学院第一附属医院药剂科(新乡 4531000)
Author(s):
LIU YuefenLIU XiaohongYU Mingjunet al.
Department of Oncology,Puyang Oilfield General Hospital(Puyang457001 )
关键词:
清金化痰汤非小细胞肺癌临床疗效VEGF水平免疫功能肿瘤标志物
Keywords:
Key words Qingjin Huatan decoction Nonsmall cell lung cancer Clinical curative effectLevels of VEGF Immune function Tumor markers
分类号:
R743.2
文献标志码:
A
摘要:
摘 要 目的 :探讨清金化痰汤治疗非小细胞肺癌患者的临床疗效。方法 :选取非小细胞肺癌患者106例,根据随机数表法分为观察组和对照组,各53例,对照组患者给予GP(吉西他滨+顺铂)方案化疗,观察组患者在此基础上给予清金化痰汤进行联合治疗,2个月为一疗程。比较两组治疗疗效,并对患者VEGF水平、免疫功能、肿瘤标志物指标水平进行比较,观察治疗过程中两组毒副反应发生情况。结果: 经过治疗,观察组患者45例有效,有效率84.91%;对照组35例有效,有效率66.04%,两组疗效差异有统计学意义(P<0.05);治疗前,两组患者VEGF水平无明显差异(P>0.05);治疗后,两组VEGFA、VEGFB、VEGFC水平均降低,且观察组降低程度较对照组明显,差异有统计学意义(P<0.05);治疗前,两组患者CD3+、CD4+、CD8+、CD4+/CD8+无明显差异(P>0.05);治疗后,两组CD3+、CD4+、CD4+/CD8+均降低,CD8+均升高,且观察组升高降低程度较对照组明显,差异有统计学意义(P<0.05);治疗前,两组患者肿瘤标志物指标水平无明显差异(P>0.05);治疗后,两组CEA、CA125、CYFRA211水平均降低,且观察组降低程度较对照组明显,差异有统计学意义(P<0.05);观察组患者出现恶心呕吐、白细胞减少、肝功受损、血小板降低、便秘等不良反应例数少于对照组,差异有统计学意义(P<0.05)。结论 :清金化痰汤治疗非小细胞肺癌患者临床疗效显著,可改善患者免疫功能,有效抑制患者VEGF水平,减少化疗的毒副反应。
Abstract:
Abstract Objective :Explore the clinical effect of Qingjin Huatan decoction in the treatment of nonsmall cell lung cancer patients. Methods:Selected 106 cases of patients with nonsmall cell lung cancer,according to the stochastic indicator method is divided into observation group and control group,53 cases,control group patients give GP (gemcitabine plus cisplatin) scheme chemotherapy,on the basis of the observation group patients give Qingjin Huatan decoction for combination therapy,2 months for a course of treatment. The efficacy of the two groups was compared,and the levels of VEGF,immune function and tumor markers were compared,and the two groups of adverse reactions were observed during the treatment. Results:After treatment,45 patients in the observation group were effective,with an effective rate of 84.91%. In the control group,35 cases were effective,and the effective rate was 66.04%,and the difference between the two groups was statistically significant (P<0.05). There was no significant difference in VEGF level between the two groups before treatment (P>0.05). After treatment,the levels of vegfa,vegfb and vegfc were all decreased in both groups,and the decrease of the observation group was significantly lower than that in the control group,with statistically significant difference (P<0.05). Before treatment,there was no significant difference between CD3+,CD4+,CD8+ and CD4+/CD8+ in the two groups (P>0.05). After treatment,both groups of CD3+,CD4+,CD4+/CD8+ decreased,and the CD8+ increased,and the decrease of the observation group was significantly lower than that in the control group,and the difference was statistically significant (P<0.05). Before treatment,there was no significant difference in markers of tumor markers in the two groups (P>0.05). After treatment,the levels of CEA,CA125 and cyfra211 were all decreased,and the decrease of the observation group was significantly lower than that in the control group,with statistically significant difference (P<0.05). The number of adverse reactions in the observation group was less than that in the control group (P<0.05). Conclusion :Qingjin Huatan decoction in the treatment of nonsmall cell lung cancer clinical curative effect significantly,can improve immune function,patients with VEGF levels were suppressed effectively reduce the side reaction of chemotherapy . 〖LM〗

参考文献/References:

\[1\] 徐玉娥,肖正国,宋 薇,等.晚期非小细胞肺癌的临床研究[J] .西部中医药,2016,29(2):14.
[2] 王煜坤,冯桂阳.中晚期非小细胞肺癌患者采用中西医结合疗法的临床治疗效果研究[J] .世界中医药,2017,12(6):13101313,1316.
[3] 谢劲松,汪建飞,奚肇庆 .中医药对肺癌患者生活质量 和生存期的影响[J] .中医学报,2015,30(11):15631565.
[4] 徐凯丽,杨珺超,韩佳颖,等.参芪扶正注射液联合化疗对晚期非小细胞肺癌患者免疫功能影响的 Meta分析[J] .中国现代应用药学,2016,33(3):352359.
[5] 王海荣.中药配合GP方案对非小细胞肺癌晚期患者生活质量及免疫功能的影响[J] .长春中医药大学学报,2015,31(1):140142.
[6] 王美阁.沙参麦冬汤加减联合化疗治疗中晚期非小细胞肺癌疗效观察[J] .临床研究,2015,23(6):13221324.
[7] 于小伟,徐 川,李 敏,等.益气固本抗癌方联合化疗对晚期非小细胞肺癌患者肿瘤标志物、炎症因子及生活质量的影响[J] .陕西中医,2016,37(7):844845.
[8] 阳 甜,陈天君,李 洋,等.非小细胞肺癌患者组织、血清白介素及血管内皮细胞生长因子的变化[J] .海南医学院学报,2014,20(9):12651266.
[9] 冯谢敏,赵 红,崔 洁,等.同步放化疗治疗局部晚期非小细胞肺癌疗效观察[J] .陕西医学杂志,2016,45(9):11261128.〖ZK)〗
[10] 周卫东,刘元铃,张 雪,等.补中益气汤合沙参麦冬汤加减联合化疗治疗非小细胞肺癌临床疗效观察[J] .实用医学杂志,2015,31(21):35973600.
[11] 李小军,陈东基,冯春兰.同步放化疗联合四君子合沙参麦冬汤治疗局部晚期非小细胞肺癌临床观察[J] .甘肃医药,2016,35(4):274277.
[12] 殷德平.艾迪注射液联合多西他赛、卡铂化疗方案对非小细胞肺癌的疗效及血清SIL2、CEA、VEGF水平的影响[J] .癌症进展,2016,14(2):179181.
[13] 陈 彬.华蟾素联合GP方案治疗中晚期非小细胞肺癌的临床疗效和抗肿瘤机理[J] .实用癌症杂志,2016,31(2):224227.
[14] 王廷祥,钭春凤.参芪扶正注射液联合化疗治疗非小细胞肺癌41例临床观察[J] .中医杂志,2014,55(9):775777.
[15] 陈银巧,朱佩祯,马 敏.沙参麦冬汤联合化疗干预中晚期非小细胞肺癌阴虚证效果观察[J] .中国乡村医药,2016,23(8):5253.
[16] 朴钟元.体外高频热疗联合中医辨证治疗气虚毒瘀型晚期非小细胞肺癌的临床研究[J] .天津中医药,2012,29(4):398401.
[17] 吕娅萍,李 春,潘新有,等.补中益气汤合沙参麦冬汤加减联合化疗治疗非小细胞肺癌临床疗效观察[J] .现代诊断与治疗,2017,28(15):27732775.
[18] 张洁霞,蔡 迪,柳元斌,等.中西医结合与纯西医治疗中晚期非小细胞肺癌的长期预后比较[J] .广东医学,2014,35(24):38993903.

相似文献/References:

[1]陈姣红,古红莉,员建中,等.参术扶正抗癌汤联合化疗及三维适形放疗对晚期非小细胞肺癌患者 血清T细胞亚群水平及生存质量的影响*[J].陕西中医杂志,2019,(5):564.
[2]张栓宝,严宁娟△,张燕平.复方斑蝥胶囊对非小细胞肺癌患者围术期血清炎症因子及免疫功能的影响[J].陕西中医杂志,2019,(7):890.
[3]任宝中,李 媛△.益气化瘀方配合化疗治疗晚期非小细胞肺癌临床研究*[J].陕西中医杂志,2019,(8):1036.
 REN Baozhong,LI Yuan..Application effect of TP chemotherapy Plus Yiqi Huayu decoction in advanced Non-small cell lung cancer patients[J].,2019,(2):1036.
[4]任东峰,孙国芳△.六君祛痰解毒汤联合化疗治疗非小细胞肺癌疗效〖JZ〗及对患者血管内皮生长因子的影响[J].陕西中医杂志,2020,(1):63.
[5]刘 婷,李 洋,石志红.灯盏花素对非小细胞肺癌A549细胞的作用及机制研究[J].陕西中医杂志,2021,(10):1363.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.009]
 LIU Ting,LI Yang,SHI Zhihong.Effects of breviscapine on proliferation and apoptosis of non-small cell lung cancer A549 cells[J].,2021,(2):1363.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.009]
[6]肖 凌,王 洋,钱建新,等.生脉饮合沙参麦冬汤联合西药治疗晚期非小细胞肺癌疗效研究[J].陕西中医杂志,2021,(12):1696.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.010]
[7]陈香梅,刘太锋,杨 明,等.复方苦参注射液联合化疗治疗非小细胞肺癌疗效研究[J].陕西中医杂志,2021,(12):1700.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.011]
[8]王理槐,孙银辉,张领兄,等.基于Wnt/β-catenin信号通路探讨血府逐瘀汤在非小细胞肺癌EGFR-TKI获得性耐药中的作用[J].陕西中医杂志,2022,(4):427.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.004]
 WANG Lihuai,SUN Yinhui,ZHANG Lingxiong,et al.Efficacy of Xuefu Zhuyu decoction in EGFR-TKI-Acquired resistance of non-small cell lung carcinoma based on the Wnt/β-catenin signaling pathway[J].,2022,(2):427.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.004]
[9]屈 直,王 芬,李志明,等.二陈汤对Lewis肺癌移植瘤生长及Hedgehog通路蛋白表达的影响[J].陕西中医杂志,2022,(5):555.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.003]
 QU Zhi,WANG Fen,LI Zhiming,et al.Effect of Erchen decoction on the expression of Hedgehog pathway protein in Lewis lung cancer transplanted tumor[J].,2022,(2):555.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.003]
[10]王军徽,肖 萌,马功贤,等.非小细胞肺癌中医药治疗研究进展[J].陕西中医杂志,2023,(11):1663.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.042]
 WANG Junhui,XIAO Meng,MA Gongxian,et al.Research progress in traditional Chinese medicine treatment of non-small cell lung cancer[J].,2023,(2):1663.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.042]

更新日期/Last Update: 2019-03-13